Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Highlights from the Literature

  • Highlights from the Literature
    What We're Reading
    Cancer Immunol Res December 1 2017 5 (12) 1057-1057;

Meeting Report

  • Meeting Report
    Report on the Third FDA–AACR Oncology Dose-Finding Workshop
    Leisha A. Emens, Rene Bruno, Eric H. Rubin, Elizabeth M. Jaffee and Amy E. McKee
    Cancer Immunol Res December 1 2017 5 (12) 1058-1061; DOI:10.1158/2326-6066.CIR-17-0590

Research Articles

  • Research Articles
    Differential Expression of Homing Receptor Ligands on Tumor-Associated Vasculature that Control CD8 Effector T-cell Entry
    Amber N. Woods, Ashley L. Wilson, Nithya Srivinisan, Jianhao Zeng, Arun B. Dutta, J. David Peske, Eric F. Tewalt, Randal K. Gregg, Andrew R. Ferguson and Victor H. Engelhard
    Cancer Immunol Res December 1 2017 5 (12) 1062-1073; DOI:10.1158/2326-6066.CIR-17-0190

    Homing receptor ligands on tumor-associated vasculature were found to vary with anatomical location and depend, in part, on intratumoral effectors. The required homing receptor/ligand interactions were identified that mediate effector CD8+ T cell entry into these tumors.

  • Research Articles
    Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T Cells
    Brian M. Olson, Melissa Gamat, Joseph Seliski, Thomas Sawicki, Justin Jeffery, Leigh Ellis, Charles G. Drake, Jamey Weichert and Douglas G. McNeel
    Cancer Immunol Res December 1 2017 5 (12) 1074-1085; DOI:10.1158/2326-6066.CIR-16-0390

    Androgen deprivation therapy (ADT), used to treat recurrent prostate cancer, can lead to overexpression of the androgen receptor. ADT combined with vaccination targeted against the androgen receptor led to improved responses in murine prostate cancer models.

  • Research Articles
    Natural Killer T-cell Immunotherapy in Combination with Chemotherapy-Induced Immunogenic Cell Death Targets Metastatic Breast Cancer
    Simon Gebremeskel, Lynnea Lobert, Kaitlyn Tanner, Brynn Walker, Tora Oliphant, Livia E. Clarke, Graham Dellaire and Brent Johnston
    Cancer Immunol Res December 1 2017 5 (12) 1086-1097; DOI:10.1158/2326-6066.CIR-17-0229

    Low-dose cyclophosphamide or gemcitabine treatments, in combination with natural killer T-cell activation therapy, modulated immune function and improved survival in a mouse model of metastatic breast cancer.

  • Research Articles
    Interleukin-12 from CD103+ Batf3-Dependent Dendritic Cells Required for NK-Cell Suppression of Metastasis
    Deepak Mittal, Dipti Vijayan, Eva M. Putz, Amelia R. Aguilera, Kate A. Markey, Jasmin Straube, Stephen Kazakoff, Stephen L. Nutt, Kazuyoshi Takeda, Geoffrey R. Hill, Nicola Waddell and Mark J. Smyth
    Cancer Immunol Res December 1 2017 5 (12) 1098-1108; DOI:10.1158/2326-6066.CIR-17-0341

    Several host factors can affect cancer metastasis. Batf3+ dendritic cells were shown in mouse models to produce the IL12 that stimulates NK cells to produce IFNγ, which helped to control cancer metastasis.

  • Research Articles | AuthorChoice
    Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity
    Karla R. Wiehagen, Natasha M. Girgis, Douglas H. Yamada, Andressa A. Smith, Szeman Ruby Chan, Iqbal S. Grewal, Michael Quigley and Raluca I. Verona
    Cancer Immunol Res December 1 2017 5 (12) 1109-1121; DOI:10.1158/2326-6066.CIR-17-0258

    This study demonstrates the advantage of combining agonist anti-CD40 with CSF-1R blockade for maximal antitumor benefit and survival in a preclinical mouse model. The results provide rationale for the combination of two distinct immunotherapies to improve clinical outcome.

  • Research Articles
    Complex Immune Evasion Strategies in Classical Hodgkin Lymphoma
    Frederik Wein, Marc A. Weniger, Benedikt Höing, Judith Arnolds, Andreas Hüttmann, Martin-Leo Hansmann, Sylvia Hartmann and Ralf Küppers
    Cancer Immunol Res December 1 2017 5 (12) 1122-1132; DOI:10.1158/2326-6066.CIR-17-0325

    Classical Hodgkin lymphoma uses multiple strategies to evade the immune system. cHL cells promoted regulatory T-cell features in CD4+ T cells and invoked additional strategies, such as purinergic signaling, to suppress immune detection.

  • Research Articles
    Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy
    Hyunju Lee, F. Stephen Hodi, Anita Giobbie-Hurder, Patrick A. Ott, Elizabeth I. Buchbinder, Rizwan Haq, Sara Tolaney, Romualdo Barroso-Sousa, Kevin Zhang, Hilary Donahue, Meredith Davis, Maria E. Gargano, Kristina M. Kelley, Rona S. Carroll, Ursula B. Kaiser and Le Min
    Cancer Immunol Res December 1 2017 5 (12) 1133-1140; DOI:10.1158/2326-6066.CIR-17-0208

    Immune checkpoint inhibitor–induced thyroid disorders were assessed in patients with a variety of cancers. Guidance is provided on monitoring and managing thyroid disorders induced by anti–PD-1 monotherapy or in combination with anti–CTLA-4.

  • Research Articles
    Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma
    Linda Tran, Clint T. Allen, Roy Xiao, Ellen Moore, Ruth Davis, So-Jin Park, Katie Spielbauer, Carter Van Waes and Nicole C. Schmitt
    Cancer Immunol Res December 1 2017 5 (12) 1141-1151; DOI:10.1158/2326-6066.CIR-17-0235

    The combination of cisplatin chemotherapy with anti–PD-1/PD-L1 immunotherapy is under investigation in clinical trials. Optimal doses of cisplatin were found to enhance the antitumor immune response, which was further improved by adding anti–PD-1/PD-L1 immunotherapy.

  • Research Articles | AuthorChoice
    Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
    Julia Tchou, Yangbing Zhao, Bruce L. Levine, Paul J Zhang, Megan M. Davis, Jan Joseph Melenhorst, Irina Kulikovskaya, Andrea L Brennan, Xiaojun Liu, Simon F. Lacey, Avery D. Posey Jr., Austin D. Williams, Alycia So, Jose R. Conejo-Garcia, Gabriela Plesa, Regina M. Young, Shannon McGettigan, Jean Campbell, Robert H. Pierce, Jennifer M. Matro, Angela M. DeMichele, Amy S. Clark, Laurence J. Cooper, Lynn M. Schuchter, Robert H. Vonderheide and Carl H. June
    Cancer Immunol Res December 1 2017 5 (12) 1152-1161; DOI:10.1158/2326-6066.CIR-17-0189

    Transiently expressed chimeric antigen receptor T cells specific for c-Met, expressed in breast cancer, were injected into breast cancer tumors of six patients in a phase 0 clinical trial. Injections resulted in tumor necrosis and were well tolerated.

Acknowledgment to Reviewers

  • Acknowledgment to Reviewers
    Acknowledgment to Reviewers
    Cancer Immunol Res December 1 2017 5 (12) 1162-1163; DOI:10.1158/2326-6066.CIR-5-12-Reviewers

Back to top
PreviousNext
Cancer Immunology Research: 5 (12)
December 2017
Volume 5, Issue 12
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

Jump to

  • Highlights from the Literature
  • Meeting Report
  • Research Articles
  • Acknowledgment to Reviewers
Advertisement
  • Most Cited
  • Most Read
Loading
  • Activity of Anti-CTLA-4 Isotypes in Antitumor Responses
  • Masters of Immunology
  • Extending Reach of Checkpoint Blockade in Pancreatic Cancer
  • PD-L1 in Triple-Negative Breast Cancer
  • Case Report: RNA CAR T Cells
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement